Endocrinology Advisor18h
FDA Alert: Endocrinology Drug News Roundup 2025
FDA drug alerts in endocrinology, including drug approvals, drug warnings, FDA medical device recalls, and FDA drug label ...
Irish Examiner21h
On the rebound: What are the long-term risks of Ozempic?
Ahead of World Obesity Day, we examine the impact of the game-changing drugs that control appetite. Increasingly being taken ...
Lexaria Bioscience Corp.: The Global Revolution in Healthcare Driven by GLP-1 Drugs and the role of Lexaria Bioscience
Lexaria executing a triple-pronged strategy in obesity and diabetesSemaglutide recently approved to treat chronic kidney disease KELOWNA, BC / ACCESS Newswire / February 27, 2025 / Lexaria Bioscience ...
NJBIZ1d
Drug compounders sue FDA over Novo Nordisk’s Ozempic, Wegovy (updated)
Drug compounders aren’t ready to give up their ability to produce off-brand versions of Novo Nordisk’s weight-loss drug ...
Novo Nordisk's Ozempic And Wegovy No Longer on FDA Shortage List, Faces Lawsuit Over Decision
A lawsuit challenges the FDA's decision to remove semaglutide from the shortage list, alleging it was arbitrary and harms ...
England subsidizes drugs like Ozempic for weight loss. Could Australia follow?
People with a high body weight living in England can now access subsidized weight-loss drugs to treat their obesity. This ...
Endocrinology Advisor2d
Novo Nordisk’s Wegovy, Ozempic No Longer in Short Supply, According to FDA
The Food and Drug Administration has determined that the shortage of Wegovy® (semaglutide) and Ozempic® (semaglutide) is resolved.
The GLP-1 Revolution — How Private Equity Investors Are Capitalizing
The business of GLP-1s, it's mass adoption, compounded GLP-1s, compounding pharmacies, venture capital, and economic impact ...
Pope Francis in critical condition with early kidney failure
Pope Francis remained in critical condition Sunday, and blood tests showed early kidney failure, but he remains alert and ...